Medicare’s GLP-1 Bridge Program: Access and Challenges

Starting in July, Medicare will introduce a GLP-1 medication program for certain beneficiaries. They will pay a single flat fee each month. This temporary initiative will last from July 1, 2026, to December 31, 2027. Despite its imminent launch, operational details remain unclear.

Program Details

The Medicare GLP-1 Bridge, termed a ‘time-limited demonstration’ by the Centers for Medicare and Medicaid Services (CMS), lets eligible Medicare Part D participants receive GLP-1 medications with a $50 monthly copay. Although GLP-1 medications are suitable for diabetes, obesity, and some heart conditions, this program targets beneficiaries seeking weight management. It aims at those without a medically coverable indication under Part D, as Medicare currently excludes weight loss medicines.

Cristy Gallagher from the Obesity Care Advocacy Network hailed the program as a major step against obesity. Yet, some regulatory experts express doubts about administration and costs. Bob Herman of Stat News noted the CMS hasn’t disclosed the cost of this 18-month program. The Hill sought more details from the Department of Health and Human Services regarding expenses.

Operational Process

The CMS states that enrollees need only a doctor’s prescription, avoiding extensive paperwork. Healthcare providers must request pre-authorization and prescribe eligible medications like Wegovy, Zepbound, or Foundayo. Switching drugs during the program necessitates a new authorization form.

Upon receiving a prescription, a pharmacist routes it to the Bridge program’s central processor, named Bridge PCN. CMS will not process pre-authorizations during prescription issuance. If the initial prescription is for the Bridge program, CMS will reject claims before sending authorization forms to providers.

The authorization requires physicians to confirm the absence of Type 2 diabetes, severe sleep apnea, or fatty liver disease in patients. Claims processing begins on July 1.

“The Medicare GLP-1 Bridge seeks to test whether providing access to GLP-1 products at a uniform CMS negotiated net price will help improve beneficiary outcomes and reduce long-term Medicare spending.” – Kelly Strachan, CMS health insurance specialist

The $50 copay does not affect deductibles or out-of-pocket maximums. Future plans after 2027 remain unclear. CMS pledges to release further information when possible.

Eligibility Criteria

Eligible participants include those in standalone drug plans or Medicare Advantage coordinated care plans. Special Needs Plan members, employer/union plan subscribers, and Limited Income Newly Eligible Transition participants are also eligible, as are Tricare For Life beneficiaries enrolled in Part D plans.

Dual Medicare and Medicaid enrollees qualify as well. Catherine Varney from the Obesity Medicine Association highlights the ideal candidates: those with obesity-related risks. Obesity links to over 200 chronic conditions, including some cancers.

Eligibility is determined by BMI. Beneficiaries must be 18 or older with a BMI of 27+, alongside conditions such as prediabetes or past cardiovascular events. Those with a BMI of 30 may include heart conditions or chronic kidney disease. For a BMI of 35+, no additional diagnosis is needed.

Regulatory Concerns

The Bridge program’s deviation from usual Medicare practices, which exclude weight loss drugs, raises potential fraud concerns. With telehealth’s rise, Christopher Frisina from Alston & Bird warns of potential misuse. Telehealth visits might become sufficient for prescriptions eligible for the Bridge model.

Frisina acknowledged the CMS’s due diligence in program setup but warned about potential fraud. He mentioned necessary coordination between providers and pharmacies through detailed pre-authorization forms, presenting checks and balances.

Despite the program details, CMS has not released cost or enrollment estimates. “CMS has not publicly released cost estimates or enrollment projections for the Medicare GLP-1 Bridge demonstration model,” an agency spokesperson stated. Adjustments to usual Medicare Part D practices mean different cost-sharing flows.